OncoOne's Focus: Targeted Therapies for Inflammation and Cancer
Inflammation
The prevalence of chronic inflammation is gaining recognition as an uncontrolled “pandemic,” negatively impacting overall life expectancy. Globally, three out of every five deaths are attributed to some form of chronic inflammatory disease. Chronic inflammatory diseases continue to present significant challenges to clinical management and consequently pose a heavy burden on society due to their increasing incidence and prevalence.
OncoOne is capitalizing on the breakthrough discovery that the pleiotropic cytokine MIF is selectively modified by the oxidative environment at sites of inflammation. oxMIF acts as an upstream regulator of other inflammatory cytokines, promoting inflammation. and aggravates inflammatory diseases through the recruitment of inflammatory cells, promoting macrophage and neutrophil infiltration and activation.
OncoOne's antibody experts are pioneering a highly selective and site-restricted approach, capitalizing on oxMIF`s specific presence at sites of inflammation, to deliver therapeutic activities only to diseased organs.
By targeting oxMIF we are poised to bring innovative and highly effective therapeutic approaches to inflammatory diseases with enormous benefits for a large and growing patient population.
Immunology Focus Areas
We work to help people living with chronic, progressive diseases live full lives without limits from their disease.
This persistent autoimmune and inflammatory condition can lead to pain, stiffness, swelling, and diminished joint function. RA may result in tissue damage, leading to chronic pain, impaired balance, and physical deformities.
Nephritis, an inflammation of the kidneys, is primarily triggered by autoimmune diseases and often leads to the excretion of high levels of protein in the urine. It affects all ages but varies by age group in cause. Common symptoms include swelling, blood in urine, infrequent urination, headaches, and drowsiness.
Asthma, a persistent inflammatory ailment, impacts individuals of all ages, with children being the most affected by this prevalent chronic disease. Inflammation and constriction of the small air passages in the lungs result in asthma symptoms, which may manifest as coughing, wheezing, difficulty breathing, and tightness in the chest.
This enduring inflammatory ailment involves inflammation of any segment of the gastrointestinal tract. Symptoms range from mild to severe, varying from person to person, and frequently oscillate between active flare-ups and periods of remission. However, they can disrupt one's regular routine.
Alzheimer's disease, the most common dementia form, is a progressive condition marked by inflammation in brain areas governing memory and language. It begins with mild memory loss, potentially progressing to severe communication and interaction impairments, significantly hindering daily activities.
Multiple sclerosis (MS) is a multifaceted autoimmune condition impacting the central nervous system (CNS), characterized by ongoing inflammation leading to the loss of neurons and their axons. Symptoms experienced by MS patients can vary greatly, encompassing motor, sensory, and cognitive impairments.
Oncology
Cancer is a leading cause of death globally with almost one in six deaths attributable to a neoplastic disorder. Projections estimate an increasing cancer incidence with over 24 million new cancer cases a year and 13 million deaths by 2030. A specific challenge to public healthcare systems is the enormous costs associated with managing cancer patients. Cancer is characterized by the expression of specific surface molecules, which are disease-specific and, antibody-based therapeutics have emerged as a promising approach in oncology.
OncoOne has developed two platform technologies to address major unmet medical needs in oncology.
Firstly, by targeting oxMIF in solid tumours OncoOne is building on the extensive experience accumulated in the field in the past 20 years, leveraging the breakthrough discovery of oxMIF. OxMIF actively promotes cancer cell proliferation, migration, and invasion while influencing various cell types within the tumor microenvironment, including immune cell recruitment, and angiogenesis.
Secondly, we exploit our expertise in antibody engineering to advance the PreTarg-it platform a radiotherapeutic approach exploiting the highly selective targeting of different tumor-associated targets at diseased sites.
OncoOne's antibody experts are paving the way for a highly selective and site-restricted approach to deliver therapeutic effects to tumors and metastatic lesions.
The antibodies in OncoOne's pipeline are poised to bring innovative and highly effective therapeutic and diagnostic approaches to patients with solid tumors, representing an eagerly anticipated development within the medical community.
Oncology Focus Areas
We work to help people living with progressive diseases live full lives without limits from their disease.
Colorectal cancer starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped together because they have many features in common.
Lung cancer is a type of cancer that starts in the lungs.
Pancreatic cancer is a type of cancer that starts in the pancreas. Pancreatic adenocarcinoma is the most common type of pancreatic cancer. Pancreatic neuroendocrine tumors (NETs) are a less common type.
Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes.
Gastrointestinal carcinoid tumors are a type of cancer that forms in the lining of the gastrointestinal (GI) tract. To understand gastrointestinal carcinoid tumors, it helps to know about the gastrointestinal system, as well as the neuroendocrine system.
Head and neck cancers can have many different names depending on where the cancer starts. For example, cancers that start in the throat (pharynx), can be called nasopharyngeal (for the upper throat behind the nose), oropharyngeal (for the middle throat behind the mouth), or hypopharyngeal (for the lower throat).
Drug Target Review Issue 3, 2023
READ NEXT
Publications and Posters
Research that inspires, data that informs, and knowledge that empowers.